Diabetes Vaccine Market Size, Shares, Trends, Outlook and Forecast to 2028. Market Analysis By Age Group, By End User, and By Geography.

Snapshot img

Pneumococcal Vaccine Market Size 2024-2028

The pneumococcal vaccine market size is forecast to increase by USD 2.85 billion at a CAGR of 5.6% between 2023 and 2028.

The market is witnessing significant growth due to expanding immunization programs by governments in developing countries and advancements in vaccine technologies. These trends are driving the market's growth, as more individuals gain access to these vital vaccines and new innovations improve their efficacy and safety. However, the high cost of vaccine development and production poses a challenge to market growth. Manufacturers must balance the need for affordability with the investment required to bring new vaccines to market. This market analysis report provides a comprehensive overview of these trends and challenges, offering valuable insights for stakeholders looking to capitalize on the opportunities presented by the market.

What will be the Size of the Pneumococcal Vaccine Market During the Forecast Period?

Request Free SampleThe market is witnessing significant growth due to the increasing prevalence of pneumococcal diseases, including pneumonia and invasive pneumococcal disease. These conditions can affect various parts of the body, such as the lungs, bloodstream, and brain covering, leading to complications like bacterial meningitis, sinusitis, and lung disease. Pneumococcal diseases disproportionately affect demographic groups with chronic conditions, such as human immunodeficiency, chronic heart disease, diabetes, and generalized musculoskeletal disorders. The pandemic situation has further highlighted the importance of immunization programs in preventing these diseases. Pipeline studies and research activities are ongoing to develop novel pneumococcal vaccines, particularly protein-based vaccines, to address the prominence of pneumococcal strains causing infections.The economic disparities in vaccine accessibility remain a challenge, with hospitalizations and mortality rates being higher in underserved populations. Despite these challenges, the market is expected to continue its growth trajectory, driven by the increasing awareness of the preventable nature of pneumococcal diseases and the ongoing efforts to improve vaccine manufacturing processes.

How is this Pneumococcal Vaccine Industry segmented and which is the largest segment?

The pneumococcal vaccine industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. TypePneumococcal conjugate vaccinePneumococcal polysaccharide vaccineDistribution ChannelNon-governmental organizationsGovernment authoritiesDistribution partner companiesGeographyNorth AmericaCanadaUSEuropeGermanyUKAsiaChinaRest of World (ROW)

By Type Insights

The pneumococcal conjugate vaccine segment is estimated to witness significant growth during the forecast period.

The pneumococcal conjugate vaccine plays a crucial role in preventing infections caused by Streptococcus pneumoniae, a bacterium responsible for pneumonia, meningitis, and sepsis. This vaccine significantly reduces the incidence of pneumonia, particularly among children under five, who were previously at high risk of hospitalization and mortality due to this disease. The global implementation of immunization programs has led to a substantial decrease in pneumonia cases, hospitalizations, and mortality rates. Immunocompromised patients, geriatric population, and those with chronic conditions such as lung disease, chronic heart disease, diabetes, human immunodeficiency, and splenectomy are also at increased risk for pneumococcal diseases. Pneumococcal strains continue to evolve, necessitating ongoing research activities and pipeline studies.The vaccine is administered through various routes, including intramuscular and intradermal injections, and is available at pharmacies, community clinics, and pediatric offices. Common side effects include redness, headache, tiredness, and generalized muscle pain. Protein-based vaccines are also under development to address the prominence of pneumococcal diseases. Despite the success of immunization programs, economic disparities and vaccine accessibility remain challenges.

Get a glance at the Pneumococcal Vaccine Industry report of share of various segments Request Free Sample

The Pneumococcal conjugate vaccine segment was valued at USD 6.71 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 41% to the growth of the global market during the forecast period.

Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The market in North America has expe

The Australia Diabetes Management Supplement market will reach USD 190 million by 2030, supported by health-conscious consumers and e-pharmacy growth.

North America Digital Vaccine Market has valued at USD 424.78 million in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 10.89%.

The Polish injectable market is projected to be valued at €500 million in 2024, driven by factors such as increasing consumer awareness and the rising prevalence of industry-specific trends. The market is expected to grow at a CAGR of 5.7%, reaching approximately €750 million by 2034.

Australia may exceed 1.42 billion US dollars by 2030, with rising CGM adoption, digital care, and personalized treatment demand.

Shingles Vaccines Market Outlook

According to our latest research, the global shingles vaccines market size reached USD 3.2 billion in 2024, and is poised to grow at a robust CAGR of 8.4% from 2025 to 2033. By the end of the forecast period, the market is expected to achieve a value of USD 6.6 billion. This impressive growth trajectory is primarily driven by increasing awareness about shingles prevention, the expanding elderly population, and the introduction of advanced recombinant vaccines. As per our comprehensive analysis, the shingles vaccines market is witnessing dynamic shifts in demand and supply, supported by favorable government initiatives and rising healthcare expenditures across both developed and emerging economies.

One of the most significant growth factors propelling the shingles vaccines market is the rising incidence of herpes zoster infections globally. Shingles, caused by the reactivation of the varicella-zoster virus, predominantly affects individuals over the age of 50, making this demographic a critical target for vaccination programs. As the global population continues to age, especially in regions such as North America, Europe, and parts of Asia Pacific, the pool of individuals at risk for shingles is expanding rapidly. This demographic trend, coupled with increased awareness campaigns by public health agencies and vaccine manufacturers, is driving higher vaccination rates and, consequently, market growth. Furthermore, the availability of highly effective recombinant vaccines with improved safety profiles has encouraged both healthcare providers and patients to opt for vaccination, further fueling demand.

Another key driver for the shingles vaccines market is the growing emphasis on preventive healthcare and immunization coverage. Governments and non-governmental organizations worldwide are actively promoting adult immunization as a means to reduce the burden of vaccine-preventable diseases, including shingles. Several countries have incorporated shingles vaccines into their national immunization schedules for older adults, supported by reimbursement policies and public funding. The expansion of healthcare infrastructure, particularly in emerging markets, has also improved vaccine accessibility, while collaborations between pharmaceutical companies and public health institutions are accelerating vaccine distribution. Additionally, technological advancements in vaccine development, such as the use of recombinant DNA technology, are resulting in more efficacious and longer-lasting vaccines, which are gaining rapid acceptance among healthcare professionals.

The shingles vaccines market is further bolstered by the increasing prevalence of immunocompromised individuals, such as those undergoing cancer treatments or living with chronic diseases like diabetes and HIV. These populations are at a higher risk of developing severe complications from shingles, making vaccination an essential preventive measure. Pharmaceutical companies are investing heavily in research and development to create vaccines that are both safe and effective for these vulnerable groups. Moreover, the growing trend of pharmacy-based immunization services is making it more convenient for individuals to receive shingles vaccines, thereby expanding the reach of vaccination programs. The convergence of these factors is creating a favorable environment for sustained market expansion over the forecast period.

From a regional perspective, North America currently dominates the shingles vaccines market, accounting for the largest share in 2024, followed by Europe and the Asia Pacific. The high market penetration in North America is attributed to robust healthcare infrastructure, strong reimbursement frameworks, and proactive public health policies. Europe is witnessing steady growth, driven by rising awareness and expanding geriatric populations, while the Asia Pacific region is emerging as a lucrative market due to increasing healthcare investments and growing adoption of adult vaccination programs. Latin America and the Middle East & Africa are also expected to witness incremental growth, albeit at a slower pace, as awareness and access to vaccines improve gradually. Regional variations in disease prevalence, healthcare spending, and government support continue to shape the global landscape of the shingles vaccines market.

The global Non-Invasive Drug Delivery Device market is poised for significant expansion, projected to reach an estimated $15,500 million by 2025 and subsequently grow at a robust Compound Annual Growth Rate (CAGR) of 18.5% through 2033. This remarkable surge is primarily propelled by the increasing prevalence of chronic diseases such as diabetes and respiratory conditions, which necessitate improved and patient-centric drug administration methods. The growing demand for painless and convenient treatment options, coupled with advancements in micro-needle and aerosol technologies, are further fueling market growth. Furthermore, the shift towards home-based healthcare and the rising adoption of smart drug delivery systems, integrated with digital health platforms, are creating new avenues for market participants. The market is segmented into applications like Diabetes Management, Vaccine Management, Pain Management, and Respiratory Management, with Diabetes Management anticipated to command the largest share due to the escalating global diabetes epidemic. The market's trajectory is further shaped by key trends such as the development of liquid-based needle-free injectors, offering greater versatility in drug formulation, and the ongoing innovation in powder-based systems for enhanced stability and ease of use, particularly for vaccines. While the market presents substantial opportunities, restraints such as high manufacturing costs, stringent regulatory approvals, and limited awareness in certain developing regions may pose challenges. However, the collaborative efforts between device manufacturers and pharmaceutical companies, aimed at developing integrated drug delivery solutions, are expected to mitigate these challenges. North America is projected to lead the market, driven by advanced healthcare infrastructure, high patient adoption rates for novel medical devices, and significant investment in R&D. Asia Pacific is expected to witness the fastest growth, attributed to the burgeoning healthcare sector, increasing disposable incomes, and a growing awareness of advanced treatment modalities. Key players like Novartis AG, Medtronic Plc., and Inovio Pharmaceuticals, Inc. are actively investing in product innovation and strategic collaborations to capitalize on these expanding market dynamics.

Explore the booming Biopharmaceuticals market, projected for substantial growth with a 7.8% CAGR. Discover key drivers, emerging trends in oncology and diabetes, and top companies shaping the future of biologic drugs.

Snapshot img

The Therapeutic Vaccines Market study is a comprehensive report with in-depth qualitative and quantitative research evaluating the current scenario and analyzing the growth of USD 3.78 billion and CAGR of 43% by segment Type and Geography during the forecast period 2019 to 2024

Furthermore, this report extensively covers the smart home appliances market segmentation by type (cancer vaccines, infectious diseases vaccines, Neurological diseases vaccines, autoimmune diseases vaccines, and other diseases vaccines) and geography (North America, Europe, Asia, and ROW). The market report also offers information on several market vendors, includingAdvantagene Inc., Aimmune Therapeutics Inc., Amgen Inc., Gilead Sciences Inc., Immune Response BioPharma Inc., Inovio Pharmaceuticals Inc., Merck & Co. Inc., Novartis AG, Sanpower Group Co. Ltd., and SOTIO AS.

Download the Report Sample to Unlock the Smart Room Heater Market Size for the Forecast Period and Other Important Statistics

Parent Market Analysis

Technavio categorizes the Therapeutic Vaccines Market as a part of the Health Care industry within the Pharmaceuticals industry. Our Technavio research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the forecast year.

Therapeutic Vaccines Market: Key Drivers, Trends, and Challenges

Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic's impact on the therapeutic vaccines industry. The holistic analysis of the drivers will help deduce end goals and refine marketing strategies to gain a competitive edge.

Key Therapeutic Vaccines Market Driver

One of the key factors driving growth in the market is the rising incidence and prevalence of diseases. The increasing incidence of several diseases such as HIV, human papillomavirus, cancer, and chronic diseases is driving the market growth. For instance, according to the CDC, 1.1 million people aged 13 years and above were diagnosed to have HIV infection in the US in 2015. Similarly, in Asian countries like India in 2017, 0.20% of the population had HIV. In Japan, in 2017, 0.10% of the population was affected by HIV. In China, 664,751 people were diagnosed to have HIV in 2016, and 124,555 new HIV infection cases were reported. Furthermore, cancer is the second-leading cause of death worldwide. According to Our World in Data, in 2016, 8.9 million people were estimated to have died from cancer. In addition, as per the NIH, in 2017, 15,270 children and adolescents aged 0-19 years were diagnosed with cancer. In 2018, 1,735,350 new cases of cancer were diagnosed in the US, and around 609,640 patients died from the disease. Furthermore, the prevalence of chronic diseases such as Alzheimer’s disease, asthma, diabetes, multiple sclerosis, and chronic obstructive pulmonary disease has increased worldwide. Various therapeutic vaccines are used for the treatment of these diseases. Therefore, the increase in the prevalence of cancer and other diseases will drive market growth during the forecast period.

Key Therapeutic Vaccines Market Challenge

The high cost of developing therapeutic vaccines will be a major challenge for the market during the forecast period. Vaccines are a potential tool to prevent and cure severe diseases. The development of vaccines to treat diseases requires significant investments, which is a challenge to the growth of the market. The cost of developing a single vaccine, from pre-clinical trials to the end of Phase IIa, can range between USD 31 million and USD 68 million, assuming no risk of failure. The development of a new vaccine candidate is estimated to cost more than USD 500 million, with further expenses required to establish facilities and equipment, which can range between USD 50 million and USD 700 million. The cost of a successful candidate could range between USD 319 million and USD 469 million. Some costs associated with vaccine development cannot be neglected to ensure adherence to the required safety standards. The US FDA approved the first therapeutic vaccine in April 2010. PROVENGE (sipuleucel-T) by Dendreon Corp. (Dendreon), a subsidiary of Sanpower Group, showed that it could extend life for about four months in men with a certain type of metastatic prostate cancer. However, the cost of PROVENGE treatment is USD 93,000 in the US. Therefore, the high cost of developing therapeutic vaccines may pose a challenge to the growth of the market.

Therapeutic Vaccines Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the therapeutic vaccines market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The

Global Digital Vaccine market was valued at USD 1.28 Billion in 2024 and is expected to reach USD 2.03 Billion by 2030 with a CAGR of 7.98%.

The prefilled needle-free injector market is experiencing significant growth, driven by increasing demand for painless and convenient drug delivery systems. The rising prevalence of chronic diseases requiring frequent injections, coupled with a growing aversion to needles, is fueling market expansion. Technological advancements leading to improved injector designs, enhanced patient comfort, and increased efficacy are further contributing to this positive trajectory. While the exact market size in 2025 requires further specification, a reasonable estimate, considering typical CAGR in medical device markets (let's assume a conservative 8% for illustration), would place the value at around $500 million, projecting substantial growth to potentially exceed $1 billion by 2033. This estimate assumes consistent adoption rates across key regions, particularly North America and Europe, which currently dominate the market due to higher healthcare spending and advanced healthcare infrastructure. Competitive dynamics are shaped by established pharmaceutical companies partnering with needle-free injector technology providers, leading to innovative product launches and increased market penetration. However, market growth faces certain restraints. Regulatory hurdles and stringent approval processes for new devices can impact market entry and expansion. The relatively high cost of needle-free injectors compared to traditional needle-based systems could also limit accessibility, particularly in price-sensitive markets. Nevertheless, ongoing research and development efforts focused on improving affordability and broadening the range of drug delivery applications are expected to mitigate these challenges. The market segmentation is largely driven by application (e.g., diabetes, vaccines, autoimmune diseases), with each segment exhibiting varying growth rates. This provides opportunities for specialized players to focus on niche applications and further accelerate market expansion. Key players are strategically investing in research and development, partnerships, and acquisitions to consolidate their market position and capitalize on emerging opportunities.

The needle-free drug delivery equipment market is experiencing robust growth, driven by increasing demand for painless injections, advancements in drug formulation, and the rising prevalence of chronic diseases requiring frequent medication. The market, estimated at $2.5 billion in 2025, is projected to witness a Compound Annual Growth Rate (CAGR) of 15% from 2025 to 2033, reaching approximately $8 billion by 2033. This significant expansion is fueled by several key factors. Firstly, patient preference for painless drug administration is a major driver. Needle-free technologies, offering reduced pain and discomfort, are increasingly preferred over traditional needle-based methods, especially among children and geriatric populations. Secondly, the development of novel drug formulations compatible with needle-free delivery systems is accelerating market growth. Thirdly, the rising incidence of chronic diseases such as diabetes, multiple sclerosis, and autoimmune disorders, requiring frequent medication, further boosts demand for convenient and less invasive delivery methods. Technological advancements, such as improved jet injectors and microneedle patches, are also contributing to the market's expansion. However, certain restraints exist, including high initial investment costs associated with adopting needle-free technologies, potential safety concerns related to specific delivery mechanisms, and regulatory hurdles in obtaining approvals for new devices. Despite these challenges, the market is segmented by technology type (jet injectors, microneedles, etc.), application (diabetes, vaccines, etc.), and end-user (hospitals, clinics, etc.), offering diverse growth opportunities. Key players like 3M, Antares Pharma, and Pharmajet are strategically focusing on product innovation and expansion into new markets to capitalize on the growing demand. The regional market is anticipated to show substantial growth across North America and Europe, driven by robust healthcare infrastructure and high adoption rates of advanced technologies. Asia-Pacific is expected to emerge as a high-growth region in the coming years, fueled by rising disposable incomes and increasing healthcare spending.

Needle-Free Injection Systems Market Outlook

According to our latest research, the global needle-free injection systems market size reached USD 1.68 billion in 2024, supported by an expanding healthcare landscape and increasing demand for pain-free drug delivery solutions. The market is expected to grow at a robust CAGR of 15.2% from 2025 to 2033, with the total value forecasted to reach USD 5.15 billion by 2033. This remarkable growth is primarily driven by heightened awareness of needle-stick injuries, rising prevalence of chronic diseases such as diabetes, and a strong push toward patient-centric innovations in drug administration devices.

One of the primary growth factors fueling the needle-free injection systems market is the increasing incidence of chronic diseases globally, particularly diabetes and various autoimmune disorders. With more than 537 million adults living with diabetes worldwide as of 2024, the need for frequent and safe drug delivery methods has become paramount. Needle-free injection systems offer a less invasive, pain-free alternative for insulin delivery, thereby significantly improving patient compliance and quality of life. Furthermore, the COVID-19 pandemic has accelerated the adoption of needle-free systems for mass vaccination campaigns, as these devices can streamline immunization processes, reduce the risk of cross-contamination, and increase patient throughput, which is especially valuable in resource-limited settings.

Technological advancements are another crucial driver of market expansion. Innovations in jet-based and microarray patch injectors have enhanced the precision, efficiency, and ease of use of needle-free injection systems, making them suitable for a broader range of applications beyond conventional vaccine and insulin delivery. The integration of digital health technologies, such as connectivity features for remote monitoring and adherence tracking, is further elevating the value proposition of these devices. As pharmaceutical companies and medical device manufacturers invest heavily in research and development, the market is witnessing a surge in novel, user-friendly products that cater to both clinical and home care environments.

Favorable regulatory frameworks and increasing investments in healthcare infrastructure, especially in emerging economies, are also bolstering the needle-free injection systems market. Governments and health organizations are actively promoting needle-free technologies to minimize the risks associated with needle-stick injuries, which account for a significant proportion of occupational hazards among healthcare professionals. Additionally, the growing emphasis on patient safety and infection control is prompting hospitals, clinics, and even home care providers to adopt needle-free alternatives. These trends are expected to sustain strong market growth over the forecast period.

The development of the Intradermal Microjet Yellow Fever Vaccine represents a significant advancement in the field of needle-free injection systems. This innovative approach utilizes microjet technology to deliver the vaccine intradermally, offering a precise and minimally invasive method for immunization. The microjet system is particularly advantageous for yellow fever vaccination campaigns in regions where traditional needle-based methods pose logistical challenges. By reducing the need for skilled healthcare personnel and minimizing the risk of needle-stick injuries, the Intradermal Microjet Yellow Fever Vaccine can enhance vaccination coverage and improve public health outcomes in endemic areas. As the global demand for efficient and safe vaccination methods continues to rise, the integration of microjet technology into vaccine delivery systems is expected to play a crucial role in addressing these needs.

From a regional perspective, North America continues to dominate the global needle-free injection systems market, accounting for over 38% of the total market share in 2024. This dominance is attributed to advanced healthcare infrastructure, high adoption rates of innovative medical devices, and supportive reimbursement policies. However, Asia Pacific is poised to witness the fastest CAGR of 17.1% through 2033, driven by rising healthcare expenditures, large patient populations, and increasing awareness of needle-free technologies in countrie

The global pre-fillable syringe market is projected to be valued at $5.2 billion in 2024, driven by factors such as increasing consumer awareness and the rising prevalence of industry-specific trends. The market is expected to grow at a CAGR of 6.2%, reaching approximately $9.5 billion by 2034.

The needle-free drug delivery devices market is projected to be valued at $5.3 billion in 2024, driven by factors such as increasing consumer awareness and the rising prevalence of industry-specific trends. The market is expected to grow at a CAGR of 8.9%, reaching approximately $12.6 billion by 2034.

The global injection puncture device market is booming, projected to reach $4.2 billion by 2033 with a 7% CAGR. This in-depth analysis explores market size, key drivers (rising chronic diseases, minimally invasive procedures), trends (needle-free injectors, home healthcare), and leading companies. Discover insights to navigate this dynamic market.

The biosimilars and subsequent entry biologics market is experiencing robust growth, driven by increasing demand for affordable alternatives to expensive branded biologics. The market, estimated at $80 billion in 2025, is projected to expand at a Compound Annual Growth Rate (CAGR) of 12% from 2025 to 2033, reaching approximately $250 billion by 2033. This growth is fueled by several key factors, including the patent expirations of several blockbuster biologics, the increasing prevalence of chronic diseases like diabetes, cancer, and cardiovascular conditions requiring biologic therapies, and supportive government policies promoting biosimilar adoption to reduce healthcare costs. Monoclonal antibodies and insulin dominate the market segments, reflecting the large patient populations requiring these therapies. However, significant growth is anticipated in other segments such as interferon and erythropoietin biosimilars as their respective patents expire. Geographical expansion into emerging markets like Asia Pacific and Middle East & Africa also contributes significantly to market expansion, driven by rising healthcare expenditure and increasing disease burden. Competitive pressures from numerous established pharmaceutical giants like Amgen, Biogen Idec, and Roche, alongside rapidly growing biosimilar manufacturers such as Celltrion and Biocon, will continue to shape the market landscape. Market restraints include regulatory hurdles associated with biosimilar approval, concerns regarding biosimilarity and efficacy compared to originator biologics, and the potential for price erosion, affecting the profitability of both biosimilar and originator companies. However, these challenges are being mitigated through enhanced regulatory frameworks, increased clinical evidence supporting biosimilar efficacy and safety, and the growing acceptance of biosimilars by healthcare professionals and patients. The market's future hinges on continued innovation in biosimilar development, improved regulatory processes, and the successful integration of biosimilars into healthcare systems globally, ultimately promoting greater access to life-saving biologics while managing healthcare costs efficiently. The diverse range of applications, from oncology to diabetes management, ensures this market will continue its trajectory of significant expansion over the forecast period.

Find detailed analysis in Market Research Intellect's Syringes And Cannulas Market Report, estimated at USD 10.5 billion in 2024 and forecasted to climb to USD 16.2 billion by 2033, reflecting a CAGR of 6.3%.Stay informed about adoption trends, evolving technologies, and key market participants.